GBIO News & Events

Satellos Bioscience (MSCLF) announced the appointment of Antoinette Paone as chief development officer and head of regulatory affairs. Paone joins Satellos from Generation Bio (GBIO), where she most recently served as COO.

Wedbush lowered the firm's price target on Generation Bio (GBIO) to $5.50 from $7 and keeps a Neutral rating on the shares. Xoma (XOMA) will acquire Generation Bio for $4.2913/share plus a non-transferable CVR, with an expected close in February 2026. The firm expects the transaction to proceed and does not anticipate other bidders. The CVR will include cash at closing in excess of $28.97M, 90%-100% of savings on Generation Bio's office lease obligations, a share of milestone and royalty payments from Moderna (MRNA), and a share of payments from out-license or sale of the ctLNP delivery platform.